Stellenwert der PET bei Kopf-Hals-Tumoren

Zusammenfassung

Die molekulare Bildgebung durch PET basiert auf dem Einsatz spezifischer radiomarkierter Moleküle als Quelle des Bildkontrastes. In der HNO wurden am häufigsten der Glukose- und vereinzelt auch der Aminosäure- und Proteinstoffwechsel zur Tumordiagnostik mit PET verwendet. Substrate des Thymidin salvage pathway und die Proliferations- sowie die Gewebshypoxiemarker haben ein hohes Potenzial zur Modulation des Strahlenfeldes bzw. zur Effizienzkontrolle zytoreduktiver Therapieschemata und werden derzeit klinisch geprüft. In dieser Kurzübersicht werden aktuelle klinische Anwendungen und Perspektiven der PET bei Kopf-Hals-Tumoren im klinischen Kontext kurz dargestellt. FDG-PET wurde zum Primärtumornachweis, zur Primärtumorsuche bei CUP-Syndrom, zum N- und M-Staging, zur Therapiekontrolle nach zytoreduktiver Therapie und zur Rezidivdiagnostik eingesetzt. Im Lymphknotenstaging und in der Rezidivdiagnostik lagen die Sensitivität und Spezifität der FDG-PET bei ca. 80 - 100 %. FDG-PET war in den meisten Studien der konventionellen bildgebenden Diagnostik überlegen. Beim CUP-Syndrom ließ sich ein Primärtumor bei Œ bis œ der Patienten lokalisieren. Die Fusionsbildgebung der PET und der CT in einem Kombinationsgerät hat wegen ihrer vielseitigen PET-basierten Detektionsprinzipien mit anatomisch hochauflösender und präziser CT-basierter morphologischer Bildgebung ein hohes klinisches und wissenschaftliches Potenzial.

Significance for ENT-tumors

Molecular imaging with PET is based on the use of specific radioactive molecules as source of image contrast. In ENT-tumors mostly glucose and occasionally amino acid/protein metabolism were assessed with PET for tumor diagnosis. Thymidine salvage pathway and proliferation as well as tissue hypoxia are tested already in clinical studies and bear considerable potential for modulation of radiation ports and therapeutic response of cytoreductive regimens. This short review summarises actual clinical indications and potential of PET in ENT-tumors. For both nodal staging as well as detection of recurrent disease, sensitivity and specifity of FDG-PET were 80 - 100 %. FDG-PET proved to be superior to conventional imaging in most published studies. In CUP-syndrome the primary could be detected in 25 - 50 % of patients.

Acquisition of PET and CT images in a combined scanner allow versatile PET based metabolic imaging in combination with high resolution and anatomical precise CT-based morphological imaging and thus combines advantages of both imaging modalities. Clinical as well as scientific potential of this functional metabolic and high resolution morphological imaging approach is high.

Schlüsselwörter

PET - Onkologie - HNO-Tumore

Key words

PET - oncology - ENT-malignomas

Literatur

• 1 Adams S, Baum R P, Stuckensen T, Bitter K, Hor G. Prospective comparison of 18F-FDG PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer.  Eur J Nucl Med. 1998;  25 1255-1260
• 2 Ambrosch P, Kron M, Fischer G, Brinck U. Micrometastases in carcinoma of the upper aerodigestive tract: detection, risk of metastasizing, and prognostic value of depth of invasion.  Head Neck. 1995;  17 473-479
• 3 Bading J R, Kan-Mitchell J, Conti P S. System A amino acid transport in cultured human tumor cells: implications for tumor imaging with PET.  Nucl Med Biol. 1996;  23 779-786
• 4 Barrington S F, Maisey M N. Skeletal Muscle Uptake of Fluorine-18-FDG: Effect of Oral Diazepam.  J Nucl Med. 1996;  37 1127-1129
• 5 Barthel H, Cleij M, Collingridge D. et al . 3′-Deoxy-3′-[18F]Fluorothymidine as a new marker for monitoring tumor response to anti-proliferate therapy in vivo with positron emission tomography.  Cancer Res. 2003;  63 3791-3798
• 6 Benchaou M, Lehmann W, Slosman D O. et al . The role of FDG-PET in the preoperative assessment of N-staging in head and neck cancer.  Acta Otolaryngold (Stockh). 1996;  116 332-335
• 7 Bergstrom M, Lundqvist H, Ericson K. et al . Comparison of the accumulation kinetics of L-(methyl-11C)-methionine and D-(methyl-11C)-methionine in brain tumors studied with positron emission tomography.  Acta Radiol. 1987;  28 225-229
• 8 Braams J, Pruim J, Nikkels P, Roodenburg J, Vaalburg W, Vermey A. Nodal Spread of Squamous Cell Carcinoma of the Oral Cavity Detected with PET-Tyrosine, MRI and CT.  J Nucl Med. 1996;  37 897-901
• 9 Braams J W, Pruim J, Freling N JM. et al . Detection of lymph node metastases of squamous-cell cancer of the head and neck with FDG-PET and MRI.  J Nucl Med. 1995;  36 211-216
• 10 Buck A, Schirrmeister H, Hetzel M. et al . F-18-FLT-PET for non-invasive assessment of proliferation in pulmonary nodules.  Cancer research. 2002;  62 3331-3334
• 11 Buck A K, Halter G, Schirrmeister H. et al . Imaging Proliferation in Lung Tumors with PET: 18F-FLT Versus 18F-FDG.  J Nucl Med. 2003;  44 1426-1441
• 12 Changlai SP, Kao CH, Chieng PU. 18F-2-fluoro-2-deoxy-D-glucose positron emission tomography of head and neck in patients with nasopharyngeal carcinomas.  Oncology Report. 1997;  4 1331-1334
• 13 Chesnay E, Babin E, Constans J M. et al . Early Response to Chemotherapy in Hypopharyngeal Cancer: Assessment with 11C-Methionine PET, Correlation with Morphologic Response, and Clinical Outcome.  J Nucl Med. 2003;  44 526-532
• 14 Choi Y, Brunken R C, Hawkins R A. et al . Factors affecting myocardial 2-[F-18]fluoro-2-deoxy-D-glucose uptake in positron emission tomography studies of normal humans.  Eur J Nucl Med. 1993;  20 308-318
• 15 Collins B T, Gardner L J, Verma A K, Lowe V J, Dunphy F R, Boyd J H. Correlation of fine needle aspiration biopsy and fluoride-18 fluorodeoxyglucose positron emission tomography in the assessment of locally recurrent and metastatic head and neck neoplasia.  Acta Cytol. 1998;  42 1325-1329
• 16 Czernin J, Phelps ME. Positron emission tomography scanning: current and future applications.  Annu Rev Med. 2002;  53 89-112
• 17 De Boer J, Pruim J, Burlage F. et al . Therapy evaluation of laryngeal carcinomas by tyrosine-PET.  Head Neck. 2003;  25 634-644
• 18 Di-Martino E, Nowak B, Hassan H A. et al . Diagnosis and staging of head and neck cancer: a comparison of modern imaging modalities (positron emission tomography, computed tomography, color-coded duplex sonography) with panendoscopic and histopathologic findings.  Arch Otolaryngol Head Neck Surg. 2000;  126 1457-1461
• 19 Di-Martino E, Nowak B, Krombach G A. et al . Ergebnisse der prätherapeutischen Lymphknotendiagnostik bei Kopf-Hals-Tumoren. Klinische Wertigkeit der 18FDG-Positronen-Emissions-Tomographie (PET).  Laryngorhinootologie. 2000;  79 201-206
• 20 Glatz S, Kotzerke J, Moog F, Sandherr M, Heimpel H, Reske S. Vortäuschung eines mediastinalen Non-Hodkin-Lymphomrezidivs durch diffuse Thymushyperplasie im 18F-FDG-PET.  Fortschr Röntgenstr. 1996;  165 309-310
• 21 Greven K M, Williams D W , Keyes J W , McGuirt W F, Watson N E , Case L D. Can positron emission tomography distinguish tumor recurrence from irradiation sequelae in patients treated for larynx cancer? [see comments].  Cancer J Sci Am. 1997;  3 353-357
• 22 Haenggeli C A, Dulguerov P, Slosman D. et al . Role de la tomographie par emission de positrons avec le 18-fluoro-deoxyglucose (PET-FDG) dans la detection precoce d'une non-sterilisation tumorale des carcinomes bucco-pharyngo-larynges.  Schweiz Med Wochenschr Suppl. 2000;  116 8S-11S
• 23 Hany T, Gharehpapahg E, Kamel E, Buck A, Himms-Hagen J, von Schulthess G K. Brown adipose tissue: a factor to consider in symmetrical tracer uptake in the neck and upper chest region.  Eur J Nucl Med. 2002;  29 1393-1398
• 24 Jager P, Vaalburg W, Pruim J, de Vries E, Langen K, Piers D. Radiolabeled amino acids: basic aspects and clinical applications in oncology.  J Nucl Med. 2001;  42 432-445
• 25 Jose J, Coatesworth A P, McLennan K. Cervical metastases in upper aerodigestive tract squamous cell carcinoma: histopathologic analysis and reporting.  Head Neck. 2003;  25 194-197
• 26 Kao C H, Chang Lai S P, Chieng P U, Yen R F, Yen T C. Detection of recurrent or persistent nasopharyngeal carcinomas after radiotherapy with 18-fluoro-2-deoxyglucose positron emission tomography and comparison with computed tomography.  J Clin Oncol. 1998;  16 3550-3555
• 27 Kau R J, Alexiou C, Laubenbacher C, Werner M, Schwaiger M, Arnold W. Lymph node detection of head and neck squamous cell carcinomas by positron emission tomography with fluorodeoxyglucose F 18 in a routine clinical setting.  Archives of Otolaryngology - Head and Neck Surgery. 1999;  125 1322-1328
• 28 Kau R J, Alexiou C, Stimmer H, Arnold W. Diagnostic procedures for detection of lymph node metastases in cancer of the larynx.  ORL J Otorhinolaryngol Relat Spec. 2000;  62 199-203
• 29 Kitagawa Y, Nishizawa S, Sano K. et al . Prospective Comparison of 18F-FDG PET with Conventional Imaging Modalities (MRI, CT, and 67Ga Scintigraphy) in Assessment of Combined Intraarterial Chemotherapy and Radiotherapy for Head and Neck Carcinoma.  J Nucl Med. 2003;  44 198-206
• 30 Kracht L, Friese M, Herholz K. et al . Methyl-[11C]-l-methionine uptake as measured by positron emission tomography correlates to microvessel density in patients with glioma.  Eur J Nucl Med Mol Imaging. 2003;  303 868-873
• 31 Kresnik E. F-18-Fluorodeoxy-Glukose-Positronenemissionstomographie in der Abklärung von Tumoren im HNO-Bereich: eigene Ergebnisse und Literaturübersicht.  Wien Med Wochenschr. 2002;  152 259-264
• 32 Kunkel M, Kuffner H D, Reichert T E, Benz P, Forster G J, Wagner W. [18F]-2-Fluordeoxyglukose-PET. Perspektiven der Sekundarprophylaxe des Mundhöhlenkarzinoms.  Mund Kiefer Gesichtschir. 2000;  4 105-110
• 33 Langen K J, Braun U, Rota Kops E. et al . The Influence of Plasma Glucose Levels on Fluorine-18-Fluorodeoxyglucose Uptake in Bronchial Carcinomas.  J Nucl Med. 1993;  34 355-359
• 34 Lapela M, Eigtved A, Jyrkkio S. et al . Experience in qualitative and quantitative FDG PET in follow-up of patients with suspected recurrence from head and neck cancer.  Eur J Cancer. 2000;  36 858-867
• 35 Laubenbacher C, Saumweber D, Wagner Manslau C. et al . Comparison of Fluorine-18-Fluorodeoxyglucose PET, MRI and Endoscopy for Staging Head and Neck Squamous-Cell Carcinomas.  J Nucl Med. 1995;  36 1747-1757
• 36 Lewis J S, McCarthy D W, McCarthy T J, Fujibayashi Y, Welch M J. Evaluation of 64-Cu-ATSM in vitro and in vivo in a hypoxic tumor model.  J Nucl Med. 1999;  40 177-183
• 37 Lindholm P, Minn H, Leskinen K allio, Bergmann J, Ruotsalainen U, Joensuu H. Influence of the Blood Glucose Concentration on FDG Uptake in Cancer - A PET Study.  J Nucl Med. 1993;  34 1-6
• 38 Lowe V, Stack B. PET Imaging in Head Neck Cancer. In: Valk P et al. (eds) Positron Emission Tomography - Basic Science and Clinical Practice. London; Springer-Verlag 2003: 535-546
• 39 Lowe V J, Boyd J H, Dunphy F R. et al . Surveillance for recurrent head and neck cancer using positron emission tomography.  J Clin Oncol. 2000;  18 651-658
• 40 McGuirt W F, Greven K M, Keyes J W , Williams D W , Watson N. Laryngeal radionecrosis versus recurrent cancer: a clinical approach.  Ann Otol Rhinol Laryngol. 1998;  107 293-296
• 41 McGuirt W F, Williams D W, Keyes J W. et al . A comparative diagnostic study of head and neck nodal metastases using positron emission tomography.  Laryngoscope. 1995;  105 373-374
• 42 Myers L L, Wax M K, Nabi H, Simpson G T, Lamonica D. Positron emission tomography in the evaluation of the N0 neck.  Laryngoscope. 1998;  108 232-236
• 43 Narayanan T, Said S, Mukherjee J. et al . A comparative study on the uptake and incorporation of radiolabeled methionine, choline and fluorodeoxyglucose in human astrocytoma.  Mol Imaging Biol. 2002;  4 147-156
• 44 Papac R J. Distant metastases from head and neck cancer.  Cancer. 1984;  53 342-345
• 45 Patel P M, Alibazoglu H, Ali A, Fordham E, LaMonica G. Normal thymic uptake of FDG on PET imaging.  Clin Nucl Med. 1996;  21 772-775
• 46 Phelps M E. Positron emission tomography provides molecular imaging of biological processes.  Proc Natl Acad Sci U S A. 2000;  97 9226-9233
• 47 Popperl G, Lang S, Dagdelen O. et al . Korrelation von FDG-PET und MRT/CT mit der Histopathologie in Primärdiagnostik, Lymphknotenstaging und Rezidivdiagnostik von Kopf-Hals-Tumoren.  Rofo Fortschr Geb Röntgenstr Neuen Bildgeb Verfahr. 2002;  174 714-720
• 48 Rasey J S, Hofstrand P D, Chin L K, Tewson T J. Characterization of [18F]fluoroetanidazole, a new radiopharmaceutical for detecting tumor hypoxia.  J Nucl Med. 1999;  40 1072-1079
• 49 Rege S, Maass A, Chaiken L. et al . Use of Positron Emission Tomography with Fluorodeoxyglucose in Patients with Extracranial Head and Neck Cancers.  Cancer. 1994;  73 3047-3058
• 50 Reske S N, Kotzerke J. FDG-PET for clinical use. Results of the 3rd German Interdisciplinary Consensus Conference, „Onko-PET III”, 21 July and 19 September 2000.  Eur J Nucl Med. 2001;  28 1707-1723
• 51 Riess H, Wust P. Tumoren des Kopf- und Halsbereiches. In: Wilmanns W, Huhn D, Wilms K (eds) Internistische Onkologie. Stuttgart, New York; Georg Thieme Verlag 1994: 572-583
• 52 Schmoll H, Höffken K, Possinger K. Kompendium Internistische Onkologie, Standards in Diagnostik und Therapie. Berlin, Heidelberg; Springer Verlag 2002
• 53 Stöcklin G, Pike V. Radiopharmaceuticals for Positron Emission Tomography - Methodological Aspects. Developments in Nuclear Medicine, ed. Cox PH. Vol. 24. Dordrecht/Boston/London; Kluwer Academic Publishers 1993
• 54 Stoeckli S J, Steinert H, Pfaltz M, Schmid S. Is there a role for positron emission tomography with 18F-fluorodeoxyglucose in the initial staging of nodal negative oral and oropharyngeal squamous cell carcinoma?.  Head Neck. 2002;  24 345-349
• 55 Stokkel M P, Terhaard C H, Hordijk G J, van-Rijk P P. The detection of local recurrent head and neck cancer with fluorine-18 fluorodeoxyglucose dual-head positron emission tomography.  Eur J Nucl Med. 1999;  26 767-773
• 56 Terhaard C H, Bongers V, van-Rijk P P, Hordijk G J. F-18-fluoro-deoxy-glucose positron-emission tomography scanning in detection of local recurrence after radiotherapy for laryngeal/pharyngeal cancer.  Head Neck. 2001;  23 933-941
• 57 Vallabhajosula S. Radiopharmaceuticals in oncology. In: Khalkhali I, Maublant J, Goldsmith S (eds) Nuclear Oncology - Diagnosis and Therapy. Philadelphia; Lippincott Williams & Wilkins 2001: 31-72
• 58 Warburg O. The metabolism of tumors. New York; Richard R. Smith Inc 1931
• 59 Weissleder R. Molecular imaging: exploring the next frontier [editorial].  Radiology. 1999;  212 609-614
• 60 Wittekind C, Meyer H, Bootz F. TNM-Klassifikation maligner Tumoren. Berlin, Heidelberg; Springer Verlag 2003
• 61 Wong W L, Chevretton E B, McGurk M. et al . A prospective study of PET-FDG imaging for the assessment of head and neck squamous cell carcinoma.  Clin Otolaryngol. 1997;  22 209-214
• 62 Zhu Z, Chou C, Yen T C, Cui R. Elevated F-18 FDG uptake in laryngeal muscles mimicking thyroid cancer metastases.  Clin Nucl Med. 2001;  26 689-691